Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran

Mycoses

Volumn 55, Issue 4, 2012, Pages 333-338

  Szigeti, Gyöngyi ^a   Sedaghati, Ebrahim ^b   Mahmoudabadi, Ali Zarei ^c   Naseri, Ali ^d   Kocsubé, Sándor ^a   Vágvölgyi, Csaba ^a   Varga, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VALI E ASR UNIVERSITY OF RAFSANJAN   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antifungal agents; Aspergillus niger; Iran; Molecular typing; Otomycosis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS AWAMORI; ASPERGILLUS NIGER; ASPERGILLUS TUBINGENSIS; FEMALE; FUNGUS ISOLATION; GENOTYPING TECHNIQUE; HUMAN; IRAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; OTOMYCOSIS; PARSIMONY ANALYSIS; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS NIGER; CALMODULIN; FEMALE; FUNGAL PROTEINS; HUMANS; IRAN; MALE; MICROBIAL SENSITIVITY TESTS; OTOMYCOSIS; PHYLOGENY;

ASPERGILLUS; ASPERGILLUS AWAMORI; ASPERGILLUS NIGER; ASPERGILLUS TUBINGENSIS;

EID: 84862248161     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02103.x     Document Type: Article

References (34)

1. Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol 2008; 72: 453-9.
2. Vennewald I, Klemm E. Otomycosis: diagnosis and treatment. Clin Dermatol 2010; 28: 202-11.
3. Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the north eastern part of Haryana. Int J Pediatr Otorhinolaryngol 2010; 74: 604-7.
4. Ghiyasi S. Survey of otomycosis in North-Western area of Iran (1995-1999). Med J Mashad Univ Med Sci 2001; 43: 85-87.
5. Kazemi A, Ghiasi S. Survey of otomycosis in north-western area of Iran. J Mazandaran Univ Med Sci 2005; 45: 112-9.
6. Kazemi AH, Nejadkazem M, Mohamadi G et al. A survey of otomycosis in Eastern Azarbaidjan. Med J Mashad Univ Med Sci 2009; 52: 233-8.
7. Zarei Mahmoudabadi A. Mycological studies in 15 cases of otomycosis. Pak J Med Sci 2006; 22: 486-8.
8. Zarei Mahmoudabadi A, Masoomi SA, Mohammadi H. Clinical and mycological studies of otomycosis. Pak J Med Sci 2010; 26: 187-90.
9. Kurnatowski P, Filipiak A. Otomycosis: prevalence, clinical symptoms, therapeutic procedure. Mycoses 2001; 44: 472-9.
10. Cheng ATL, Young NM. Inflammatory diseases of the ear. Indian J Pediatr 1997; 64: 747-53.
11. Bonifaz A, Chavolla-Magana R, Araiza J. Aspergillus otitis. In: Pasqualotto AC (ed.), Aspergillosis: From Diagnosis to Prevention. Dordrecht: Springer Science & Business Media, 2010: 999-1006.
12. Gams W, Christensen M, Onions AH, Pitt JI, Samson RA. Infrageneric taxa of Aspergillus. In: Samson RA, Pitt JI (eds), Advances in Penicillium and Aspergillus Systematics. New York: Plenum Press, 1985: 55-62.
13. Samson RA, Noonim P, Meijer M, Houbraken J, Frisvad JC, Varga J. Diagnostic tools to identify black aspergilli. Stud Mycol 2007; 59: 129-45.
14. Peterson SW. Phylogenetic analysis of Aspergillus species using sequences from four loci. Mycologia 2008; 100: 205-26.
15. Varga J, Kocsubé S, Tóth B et al. Aspergillus brasiliensis sp. nov., a biseriate black Aspergillus species with world-wide distribution. Int J Syst Evol Microbiol 2007; 57: 1925-32.
16. Balajee SA, Kano R, Baddley JW et al. Molecular identification of Aspergillus species: Transplant Associated Infection Surveillance Network (TRANSNET). J Clin Microbiol 2009; 47: 3138-41.
17. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 2009; 53: 4514-7.
18. Arthur RR, Drew RH, Perfect JR. Novel modes of antifungal drug administration. Expert Opin Investig Drugs 2004; 13: 903-32.
19. Hong SB, Cho HS, Shin HD, Frisvad JC, Samson RA. Novel Neosartorya species isolated from soil in Korea. Int J Syst Evol Microbiol 2006; 56: 477-86.
20. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-9.
21. Hillis DM, Bull JJ. An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst Biol 1993; 42: 182-92.
22. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard, Document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
23. Perrone G, Stea G, Epifani F, Varga J, Frisvad JC, Samson RA. Aspergillus niger contains the cryptic phylogenetic species A. awamori. IMC9 (9th International Mycological Congress), Edinburgh, 1-6 August, 2010, Poster No. P1.101.
24. Yenisehirli G, Bulut Y, Güven M, Günday E. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens. J Laryng Otol 2009; 123: 978-81.
25. Karaarslan A, Arikan S, Ozcan M, Ozcan KM. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis. Mycoses 2004; 47: 284-7.
26. Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother 2001; 45: 1882-5.
27. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780-1.
28. Aktas E, Yigit N. Determination of antifungal susceptibility of Aspergillus spp. responsible for otomycosis by E-test method. J Mycol Med 2009; 19: 122-5.
29. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
30. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009; 53: 2192-5.
31. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99-131.
32. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for chinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-9.
33. Kredics L, Varga J, Kocsubé S et al. Infective keratitis due to Aspergillus tubingensis. Cornea 2009; 28: 951-4.
34. Pagiotti R, Angelini P, Rubini A, Tirillini B, Granetti B, Venanzoni R. Identification and characterisation of human pathogenic filamentous fungi and susceptibility to Thymus schimperi essential oil. Mycoses 2010; doi: